Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Five-Month Follow-up Shows No Improvement in Dermatological Complications in Children With Type 1 Diabetes Using Continuous Glucose Monitoring Systems and Insulin Pumps

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Telemedicine Consultations and Diabetes Technology During COVID-19

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Analyzing the Potential of Advanced Insulin Dosing Strategies in Patients With Type 2 Diabetes: Results From a Hybrid In Silico Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Six-Year Follow-Up After Insulin Pump Initiation: HbA1c Is Significantly Reduced Without Weight Gain

    Research output: Contribution to journalLetterpeer-review

  1. Trajectories of Childhood Adversity and Type 1 Diabetes: A Nationwide Study of One Million Children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Contact dermatitis caused by glucose sensors, insulin pumps, and tapes: Results from a 5-year period

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

    Research output: Contribution to journalReviewpeer-review

View graph of relations

BACKGROUND: A Danish study showed that 90% of the pediatric patients who participated had some time experienced dermatological complications due to treatment with continuous subcutaneous insulin infusion (CSII). This follow-up study describes dermatological complications due to CSII and/or continuous glucose monitoring (CGM) between the two study periods and includes health-related quality of life (HrQoL) measurements.

METHODS: A total of 138 patients (95%) out of 145 patients from the initial study answered an online questionnaire regarding dermatological complications related to CSII and/or CGM, five months later. A second questionnaire (DISABKIDS) regarding HrQoL was sent out to those 138 of which 111 patients completed it. The patients were aged from 2 to 20 years. Descriptive statistics, χ2 tests, and univariate and multivariate analyses were used to analyze the data.

RESULTS: In total, 81% of the 138 patients continued to have dermatological complications at follow-up. Itching was the most frequently reported complication. Patients using Enlite reported more dermatological complications than those using Libre. In total, 79% of the patients who used barrier cream in the initial study still had dermatological complications five months later. Age, gender, Body Mass Index (BMI), or HbA1c levels showed no significant association with dermatological complications. Patients who perceived dermatological complications as a greater problem had lower HrQoL scores.

CONCLUSION: Once dermatological complications start to appear, they become chronic, indicating that the treatments currently available are inadequate. Patients perceiving dermatological complications as a greater problem were associated with lower HrQoL. These findings highlight the need for additional preventive studies.

Original languageEnglish
JournalJournal of diabetes science and technology
Pages (from-to)1932296819882425
ISSN1932-2968
DOIs
Publication statusPublished - 2021

ID: 59237575